鼻腔给药
医学
纳米载体
临床试验
药物输送
重症监护医学
食品药品监督管理局
药品
药理学
内科学
纳米技术
材料科学
作者
Tyler P. Crowe,Walter H. Hsu
出处
期刊:Pharmaceutics
[MDPI AG]
日期:2022-03-12
卷期号:14 (3): 629-629
被引量:41
标识
DOI:10.3390/pharmaceutics14030629
摘要
Neurological diseases continue to increase in prevalence worldwide. Combined with the lack of modifiable risk factors or strongly efficacious therapies, these disorders pose a significant and growing burden on healthcare systems and societies. The development of neuroprotective or curative therapies is limited by a variety of factors, but none more than the highly selective blood-brain barrier. Intranasal administration can bypass this barrier completely and allow direct access to brain tissues, enabling a large number of potential new therapies ranging from bioactive peptides to stem cells. Current research indicates that merely administering simple solutions is inefficient and may limit therapeutic success. While many therapies can be delivered to some degree without carrier molecules or significant modification, a growing body of research has indicated several methods of improving the safety and efficacy of this administration route, such as nasal permeability enhancers, gelling agents, or nanocarrier formulations. This review shall discuss promising delivery systems and their role in expanding the clinical efficacy of this novel administration route. Optimization of intranasal administration will be crucial as novel therapies continue to be studied in clinical trials and approved to meet the growing demand for the treatment of patients with neurological diseases.
科研通智能强力驱动
Strongly Powered by AbleSci AI